Better Buy After the Cloud Stock Sell-Off: Oracle or Salesforce?

Oracle reported fiscal Q4 revenue of $19.2B, up 21% year over year, and its remaining performance obligations jumped to $638B, but free cash flow was negative $23.7B amid heavy AI data-center spending and expected net capital spending of about $70B this fiscal year. Salesforce posted Q1 revenue of $11.1B, up 13%, generated $6.6B of free cash flow, and said Agentforce ARR reached $1.2B, up 205% year over year. The article argues Salesforce is the better buy at roughly 19x earnings versus Oracle at about 32x, though both stocks face AI-related risk.

Analysis

The market is splitting these two names on the wrong axis. Oracle is being treated like a pure growth winner, but the hidden issue is balance-sheet duration mismatch: the company is monetizing long-dated AI demand with near-term leverage, which means equity holders are effectively underwriting a financing machine before they own the cash flows. That creates a classic late-cycle setup where the stock can stay expensive until credit investors or capex discipline force a re-rate.

Salesforce, by contrast, is being priced for structural obsolescence while still throwing off surplus cash and using it to defend the capital return story. The second-order implication is that AI may compress seat-based SaaS growth, but it can also expand attach rates in workflow, data, and automation layers where CRM already sits; the threat is less immediate substitution than slower pricing power over time. That makes the market's reaction look more like an algorithmic de-rating of duration than a fundamental break in the franchise.

The real divider is financing regime. Oracle's backlog is an asset only if debt markets remain tolerant of multi-year negative FCF and if AI buildout ROI stays intact; any hiccup in delivery, pricing, or utilization could turn the backlog into a working-capital trap. Salesforce has the opposite profile: if management can prove even modest acceleration from AI products into FY27, the stock can rerate quickly because expectations are already near trough multiples.

Key Decisions for Investors

• Go long CRM vs short ORCL in a market-neutral pair for 3-6 months: CRM offers positive FCF, buybacks, and lower financing risk; ORCL has more upside only if capex efficiency improves, so the pair isolates the funding-risk spread.
• Buy CRM Jan-2027 calls or call spreads on weakness: the setup is asymmetric because sentiment is already discounting disruption, while any evidence of AI monetization into FY27 should expand multiple and earnings expectations simultaneously.
• Avoid initiating fresh long ORCL ahead of the next capex/debt update; if you must own it, use call spreads rather than stock to cap downside from a credit-driven de-rating over the next 1-2 quarters.
• Watch INFA as a secondary beneficiary/confirmation trade over the next 1-3 months: if enterprise data stack consolidation accelerates, INFA can capture budget share whether AI agents win or SaaS seat counts slow.
• Use ORCL weakness only on evidence of improving capex intensity or debt absorption; otherwise treat it as a momentum trade, not a fundamental long, because the payoff is years out while financing risk is immediate.